A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age12+
SponsorRecursion Pharmaceuticals Inc.
About this trial
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Eligibility criteria
Qualifiers
Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
Disqualifiers
Received treatment with another RBM39 degrader
Clinically significant gastrointestinal (GI) or GI malabsorption
Trial design
Treatments tested in this trial
- REC-1245
Treatment groups
170 Participants
are divided into 9 treatment groups9
Treatment groupsSee each treatment group below.
Locations
6Canada
Princess Margaret Cancer CentreM5G 1X6, TorontoOntario, Canada
McGill University Health Centre (MUHC) - The MontrealH4A3J1, Québec Canada
United States
City of Hope91010, DuarteCalifornia, United States
Cleveland Clinic44195, ClevelandOhio, United States
Sponsors and collaborators
Recursion Pharmaceuticals Inc.
Lead sponsor
Source ClinicalTrials.gov